<DOC>
	<DOCNO>NCT01240096</DOCNO>
	<brief_summary>Double-blind randomize control trial 8 week mirtazapine 15 mg daily placebo , follow 8 week open-label mirtazapine 15 mg daily</brief_summary>
	<brief_title>Mirtazapine Versus Placebo Functional Dyspepsia</brief_title>
	<detailed_description>Double-blind randomize control trial 8 week mirtazapine 15 mg placebo , follow 8 week open-label mirtazapine Two week run-in , 8 week randomize , 8 week open label Assessments include - dyspepsia questionnaire - Nepean dyspepsia index - Daily diary - Vital sign</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Functional dyspepsia accord Rome II criterion Weight loss &gt; 5 % body weight Organic GI pathology History upper gi tract surgery Major depression anxiety Use antidepressant last 2 month Prokinetic drug spasmolytic drug Analgesic use ( except paracetamol ) Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Functional dyspepsia</keyword>
	<keyword>Weight loss</keyword>
	<keyword>Mirtazapine</keyword>
</DOC>